News >

Pembrolizumab Shows Promise for Unmet Need in NMIBC

Brandon Scalea
Published: Wednesday, May 22, 2019

Arjun V. Balar, MD

Arjun V. Balar, MD
Early data indicate that pembrolizumab (Keytruda) is a feasible option for patients with high-risk nonmuscle–invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG), explained Arjun V. Balar, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication